Viridian Therapeutics, Inc.\DE - Common Stock, par value $0.01 per share (VRDN)

CUSIP: 92790C104

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 6 signals
Share change
-123,079
SEC-reported price per share
$20.59
Number of holders
25
Value change
-$2,231,754
Number of buys
14
Number of sells
9
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
113,750,140

Security key

92790C104

Report period

Q3 2026

Institutions

25

Top holders

10

Ownership snapshot

Top reported holders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
FMR LLC
Comparable rows
10/15
Latest evidence
19 Aug 2026
13D/G 3/4/5 13F Lead comparable stake: 14% 5 rows are not safely comparable across share classes. 13D/G row: Fairmount Funds Management LLC Showing 1-6 of 15 holder rows.

Quick read

Fairmount Funds Management LLC leads the comparable SEC ownership view at 14%.

10 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership Top 5
Fairmount Funds Management LLC 14%
Bellevue Group AG 6.6%
Paradigm Biocapital Advisors LP 6.1%
Kynam Capital Management, LP 5.7%
STATE STREET CORP 5.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Fairmount Funds Management LLC
13D/G 3/4/5 13F
Director, 10%+ Owner · Company
14%
Reported 13D/G · 11 May 2026
$239,105,020
17,201,800 shares
+$16,352,933 11 May 2026
Bellevue Group AG
13F 13D/G
Company
6.6%
Reported 13D/G · 31 Mar 2026
$123,665,169
6,731,909 shares
— 30 Jun 2026
Paradigm Biocapital Advisors LP
13D/G 13F
Company
6.1%
Reported 13D/G · 30 Jun 2026
$132,727,575
6,723,788 shares
+$21,516,600 30 Jun 2026
Kynam Capital Management, LP
13F 13D/G
Company
5.7%
Reported 13D/G · 30 Jun 2026
$118,557,720
6,453,877 shares
— 30 Jun 2026
STATE STREET CORP
13D/G 13F
STATE STREET CORPORATION · Company
5.5%
Reported 13D/G · 30 Jun 2026
$120,907,026
6,124,976 shares
$0 30 Jun 2026
PRICE T ROWE ASSOCIATES INC /MD/
13D/G 13F
T. Rowe Price Associates, Inc. · Company
5.2%
Reported 13D/G · 30 Jun 2026
$113,473,929
5,748,426 shares
$0 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
25
Shares
528,514
Rows available
25
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
213
Q3 2026 holders
25
Holder diff
-188
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .